BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 12872355)

  • 1. Symptoms and signs of primary melanoma: important indicators of Breslow depth.
    Negin BP; Riedel E; Oliveria SA; Berwick M; Coit DG; Brady MS
    Cancer; 2003 Jul; 98(2):344-8. PubMed ID: 12872355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.
    Paek SC; Griffith KA; Johnson TM; Sondak VK; Wong SL; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
    Cancer; 2007 Jan; 109(1):100-8. PubMed ID: 17146784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breslow depth of cutaneous melanoma: impact of factors related to surveillance of the skin, including prior skin biopsies and family history of melanoma.
    Fisher NM; Schaffer JV; Berwick M; Bolognia JL
    J Am Acad Dermatol; 2005 Sep; 53(3):393-406. PubMed ID: 16112344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics.
    Schwartz JL; Wang TS; Hamilton TA; Lowe L; Sondak VK; Johnson TM
    Cancer; 2002 Oct; 95(7):1562-8. PubMed ID: 12237926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An increased number of sentinel lymph nodes is associated with advanced Breslow depth and lymphovascular invasion in patients with primary melanoma.
    Schmidt CR; Panageas KS; Coit DG; Patel A; Brady MS
    Ann Surg Oncol; 2009 Apr; 16(4):948-52. PubMed ID: 19194758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy.
    Morris KT; Busam KJ; Bero S; Patel A; Brady MS
    Ann Surg Oncol; 2008 Jan; 15(1):316-22. PubMed ID: 18004626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
    Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
    Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution.
    Roulin D; Matter M; Bady P; Liénard D; Gugerli O; Boubaker A; Bron L; Lejeune FJ
    Eur J Surg Oncol; 2008 Jun; 34(6):673-9. PubMed ID: 17825518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
    Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
    Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does shave biopsy accurately predict the final breslow depth of primary cutaneous melanoma?
    Moore P; Hundley J; Hundley J; Levine EA; Williford P; Sangueza O; McCoy T; Shen P
    Am Surg; 2009 May; 75(5):369-73; discussion 374. PubMed ID: 19445285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological analysis of 1571 cutaneous malignant melanomas in Valencia, Spain: factors related to tumour thickness.
    Nagore E; Oliver V; Botella-Estrada R; Moreno-Picot S; Guillén C; Fortea JM
    Acta Derm Venereol; 2006; 86(1):50-6. PubMed ID: 16585990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France.
    Grange F; Vitry F; Granel-Brocard F; Lipsker D; Aubin F; Hédelin G; Dalac S; Truchetet F; Michel C; Batard ML; Baury B; Halna JM; Schmutz JL; Delvincourt C; Reuter G; Dalle S; Bernard P; Danzon A
    Arch Dermatol; 2008 May; 144(5):629-36. PubMed ID: 18490589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma.
    Lee JH; Essner R; Torisu-Itakura H; Wanek L; Wang H; Morton DL
    J Clin Oncol; 2004 Sep; 22(18):3677-84. PubMed ID: 15365064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel lymph node biopsy in elderly irish patients with malignant melanoma.
    Moran DE; Smith MJ; O'Sullivan MJ; Bannon H; Crotty TB; Collins CD; Skehan SJ; O'Higgins N; McDermott EW; Evoy D; Hill AD
    Ir Med J; 2007 Apr; 100(4):422-4. PubMed ID: 17566474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors related to the presentation of thin and thick nodular melanoma from a population-based cancer registry in Queensland Australia.
    Geller AC; Elwood M; Swetter SM; Brooks DR; Aitken J; Youl PH; Demierre MF; Baade PD
    Cancer; 2009 Mar; 115(6):1318-27. PubMed ID: 19189368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.
    Kruper LL; Spitz FR; Czerniecki BJ; Fraker DL; Blackwood-Chirchir A; Ming ME; Elder DE; Elenitsas R; Guerry D; Gimotty PA
    Cancer; 2006 Nov; 107(10):2436-45. PubMed ID: 17058288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subungual melanoma: a study of 124 cases highlighting features of early lesions, potential pitfalls in diagnosis, and guidelines for histologic reporting.
    Tan KB; Moncrieff M; Thompson JF; McCarthy SW; Shaw HM; Quinn MJ; Li LX; Crotty KA; Stretch JR; Scolyer RA
    Am J Surg Pathol; 2007 Dec; 31(12):1902-12. PubMed ID: 18043047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microstaging accuracy after subtotal incisional biopsy of cutaneous melanoma.
    Karimipour DJ; Schwartz JL; Wang TS; Bichakjian CK; Orringer JS; King AL; Huang CC; Johnson TM
    J Am Acad Dermatol; 2005 May; 52(5):798-802. PubMed ID: 15858469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.
    Berk DR; Johnson DL; Uzieblo A; Kiernan M; Swetter SM
    Arch Dermatol; 2005 Aug; 141(8):1016-22. PubMed ID: 16103331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors.
    Lindholm C; Andersson R; Dufmats M; Hansson J; Ingvar C; Möller T; Sjödin H; Stierner U; Wagenius G;
    Cancer; 2004 Nov; 101(9):2067-78. PubMed ID: 15372475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.